{
    "clinical_study": {
        "@rank": "68699", 
        "arm_group": [
            {
                "arm_group_label": "head and neck", 
                "arm_group_type": "Experimental", 
                "description": "Cetuximab, 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly there after Eribulin  Mesylate 1.4mg/m2"
            }, 
            {
                "arm_group_label": "Colon", 
                "arm_group_type": "Experimental", 
                "description": "Eribulin Mesylate:\n1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the full dose of eribulin mesylate can be\n      safely given with the full dose of cetuximab. The activity of the combination of eribulin\n      mesylate and cetuximab on recurrent head and neck cancer and colon cancer will also be\n      assessed."
        }, 
        "brief_title": "A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Head and Neck Cancer", 
            "Colon Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colonic Neoplasms", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "To determine if eribulin mesylate, up to a maximum dose of 1.4 mg/m2 day 1 and 8 of a 21 day\n      cycle, can be safely combined with full dose cetuximab for patients with advanced head and\n      neck cancer and colon cancer"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Histologically or cytologically confirmed advanced squamous cell cancer of the head\n             and neck with progression after at least one prior therapy. (Chemoradiation is\n             considered one line of therapy)\n\n          -  In the dose escalation cohorts, patients with advanced colon adenocarcinoma with\n             wild-type kras who have previously received at least two lines of therapy for\n             advanced disease are eligible.\n\n          -  Life expectancy of at least 3 months\n\n          -  Patients must be aged 18 years or older\n\n          -  Patients with measurable tumors according to RECIST .\n\n          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status\n             0-1\n\n          -  No severe concurrent illness that would interfere with protocol therapy.\n\n          -  Patients must have adequate renal function as evidenced by  \u22641.5 mg/dL or creatinine\n             clearance > 40 mL/minute (min).\n\n          -  Patients must have adequate bone marrow function as evidenced by absolute neutrophil\n             count (ANC) > 1.5 x 109/L and platelet count > 100 x 109/L.\n\n          -  Patients must have adequate hepatic function as evidenced by bilirubin \u2264 1.5 times\n             the upper limit of normal (ULN) and alanine aminotransferase (ALT), and aspartate\n             aminotransferase (AST) \u2264 3 x ULN (in the case of liver metastases ALT and AST \u2264 5 x\n             ULN).\n\n          -  Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or\n             below, except for alopecia.\n\n          -  Patients must be willing and able to comply with the study protocol for the duration\n             of the study.\n\n          -  Patients must give written informed consent prior to any study-specific screening\n             procedures with the understanding that the patient may withdraw consent at any time\n             without prejudice.\n\n          -  No other active invasive malignancy unless disease free for at least 2 years.\n\n        Exclusion Criteria\n\n          -  In the final expansion cohort, no prior treatment with EGFR inhibitor.\n\n          -  Patients who received chemotherapy or investigational therapy within 3 weeks before\n             treatment initiation. Radiation must be completed within 2 weeks before treatment\n             initiation.\n\n          -  Patients with a hypersensitivity to cetuximab.\n\n          -  Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical\n             derivative.\n\n          -  Patients who participated in a prior eribulin mesylate clinical trial, whether or not\n             they received eribulin mesylate.\n\n          -  Patients with other significant disease or disorders that, in the investigator's\n             opinion, would exclude the patient from the study.\n\n          -  Women who are pregnant or breast-feeding; women of childbearing potential with either\n             a positive pregnancy test at screening or no pregnancy test; women of childbearing\n             potential unless (1) surgically sterile or (2) using adequate measures of\n             contraception in the opinion of the Investigator. Peri-menopausal women must be\n             amenorrheic for at least 12 months to be considered of non-childbearing potential.\n\n          -  Patients with brain or subdural metastases are not eligible, unless they have\n             completed local therapy and have discontinued the use of corticosteroids for this\n             indication for at least 4 weeks before starting treatment in this study. Any signs\n             (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least 4\n             weeks.\n\n          -  Grade 2 or worse neuropathy.\n\n          -  Significant cardiovascular impairment (history of congestive heart failure > NYHA G\n             II, unstable angina or myocardial infarction within the past six months, or serious\n             cardiac arrhythmia.\n\n          -  QTc > 500 msec"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744340", 
            "org_study_id": "BrUOG 254"
        }, 
        "intervention": [
            {
                "arm_group_label": "head and neck", 
                "description": "Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter\nDose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle", 
                "intervention_name": "Head and neck", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Colon", 
                "description": "Eribulin Mesylate:\n1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle", 
                "intervention_name": "Colon", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cetuximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Head and Neck", 
            "Colon"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "kayla_rosati@brown.edu", 
                    "last_name": "Kayla rosati", 
                    "phone": "401-863-3000"
                }, 
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10467"
                    }, 
                    "name": "Montefiore"
                }, 
                "investigator": {
                    "last_name": "Lakshmi Rajdev, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "patti_wingate@mhri.org", 
                    "last_name": "Patti Wingate", 
                    "phone": "401-729-2225"
                }, 
                "facility": {
                    "address": {
                        "city": "Pawtucket", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02860"
                    }, 
                    "name": "Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Anthony Thomas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kayla_rosati@brown.edu", 
                    "last_name": "kayla rosati", 
                    "phone": "401-863-3000"
                }, 
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02903"
                    }, 
                    "name": "Rhode Island Hospital"
                }, 
                "investigator": {
                    "last_name": "Howard Safran, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mjean@lifespan.org", 
                    "last_name": "Marueen Jean", 
                    "phone": "401-793-4283"
                }, 
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02904"
                    }, 
                    "name": "The Miriam Hospital"
                }, 
                "investigator": {
                    "last_name": "Howard Safran, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Kayla_rosati@brown.edu", 
                    "last_name": "Kayla Rosati", 
                    "phone": "401-863-3000"
                }, 
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02908"
                    }, 
                    "name": "Roger Williams Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ritesh Rathore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study", 
        "overall_contact": {
            "email": "Kayla_rosati@brown.edu", 
            "last_name": "Kayla Rosati", 
            "phone": "401-863-3000"
        }, 
        "overall_official": {
            "affiliation": "Brown University Oncology Research Group", 
            "last_name": "Howard Safran, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Toxicity of eribulin mesylate combined with full dose cetuximab for patients with advanced head and neck cancer and colon cancer.", 
            "safety_issue": "Yes", 
            "time_frame": "From beginning of treatment to 30 days post being off drug, an expected average of 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744340"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brown University", 
            "investigator_full_name": "howard safran", 
            "investigator_title": "Prinicipal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Response rate (whether patient's disease is progressing or being controlled) of patients with head and neck cancer treated with eribulin mesylate and cetuximab.", 
            "safety_issue": "No", 
            "time_frame": "From beginning of treatment to progression of disease, for an expected average of 1 year"
        }, 
        "source": "Brown University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Fatima Memorial Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Montefiore Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Roger Williams Medical Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "howard safran", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}